Merrill Shum, Hematologist-Oncologist at Cancer and Blood Specialty Clinic, shared a post on LinkedIn by Cancer and Blood Specialty Clinic, adding:
“Waiting with great anticipation for FDA approval. In the meantime, we will do our part in obtaining Darazonrasib for our pancreatic cancer patients through the expanded access program (EAP).”
Quoting Cancer and Blood Specialty Clinic’s post:
“Darazonrasib – now available in the SoCal community oncology setting at the Cancer and Blood Specialty Clinic – Fountain Valley Office through expanded access.”
You can also read ESMO Clinical Practice Guideline Express Update: Daraxonrasib for Metastatic Pancreatic Cancer on OncoDaily.
